AlzeCure Pharma, a Swedish pharmaceutical company, has announced the receipt of patent approval awards for its clinical drug candidate ACD856 in several countries, including China. The drug, which holds potential as a treatment for Alzheimer’s disease and other cognitive impairment-related disorders, has been granted protection until 2039 in China, India, South Africa, Israel, Hong Kong, and Mexico. These recent awards complement earlier patent approvals covering the United States and the European Union.
ACD856, developed on AlzeCure’s NeuroRestore platform, is designed to stimulate neurotrophic signaling pathways, thereby enhancing nerve cell function and improving memory. The drug’s active ingredients target BDNF (Brain Derived Neurotrophic Factor) and NGF (Nerve Growth Factor). ACD856 completed a Phase I clinical trial in 2022, demonstrating good safety and tolerability in humans and showing an ability to cross the blood-brain barrier to activate regions of the brain central to cognition and depression treatment. New preclinical results indicate potential neuroprotective and disease-modifying effects with these substances. AlzeCure has expressed openness to licensing and/or partnership deals regarding the global development of its drug candidate.- Flcube.com
